An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.
Source summary generated July 17, 2026; this date does not indicate completed review.
Quotes from three independent practitioners, with their sources. Research context only.
What it is and how it works
From the published literature on 5-Amino-1MQ; the papers are listed at the end. Research summary, not a recommendation.
What it is
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic molecule, not a peptide. It belongs to a family of methylquinolinium compounds designed at the University of Texas Medical Branch in Galveston to block the enzyme nicotinamide N-methyltransferase (NNMT), and most of its published research comes from that group and its spin-out company, Ridgeline Therapeutics. It is not an approved drug and is sold as a research chemical.
How it works
NNMT is an enzyme, abundant in fat and liver tissue, that attaches a methyl group to nicotinamide (a form of vitamin B3). In doing so it uses up the cell's methyl donor (SAM) and diverts nicotinamide away from making NAD+, a molecule cells need to burn fuel. Mice in which NNMT was switched off in fat and liver gained less weight on a high-fat diet and burned more energy. In cultured fat cells, 5-amino-1MQ lowered the NNMT product (1-MNA), raised NAD+ and SAM, and reduced fat production. In obese mice it reduced weight gain and fat mass without lowering food intake, and in aged mice it reactivated muscle stem cells after injury.
What it has been studied for
Diet-induced obesity and fat mass (mouse studies)
Insulin sensitivity and fatty liver (mouse studies)
Weight loss combined with a lower-calorie diet (mouse studies)
Muscle regeneration in aged animals (mouse studies)
NNMT as a metabolic and epigenetic drug target (reviews and genetic studies)
Strength of the evidence
Animal and lab studiesAll published work on 5-amino-1MQ is in cells and mice, mostly from the developing group; no human trial has been published.
What the literature reports on safety
The mouse studies reported no observable adverse effects and no change in food intake, but no human safety or pharmacology study has been published, so the human adverse-effect profile is unknown. 5-amino-1MQ is not approved by the FDA or any other regulator. Several of the key studies list competing interests, because authors were founders or employees of the company developing NNMT inhibitors.
Review · Roberti A, Fernández AF, et al. · Molecular Metabolism (2021) · PMID 33453420
Reviewed how NNMT links vitamin B3 metabolism, methyl-group supply and gene regulation, and why it became a target in obesity, liver disease and cancer.
Animal study · Kraus D, Yang Q, et al. · Nature (2014) · PMID 24717514
Genetically lowering NNMT in fat and liver of mice increased energy expenditure and protected against diet-induced obesity, the finding that motivated NNMT-inhibitor drugs.
Animal study · Neelakantan H, Vance V, et al. · Biochemical Pharmacology (2018) · PMID 29155147
Methylquinolinium NNMT inhibitors raised NAD+ and SAM and reduced fat production in fat cells, and reduced body weight and white fat in obese mice without changing food intake.
Animal study · Babula JJ, Bui D, et al. · Diabetes, Obesity and Metabolism (2024) · PMID 39161060
Over four weeks in obese mice, 5-amino-1MQ limited weight and fat gain, improved glucose tolerance and insulin sensitivity, and reduced fatty liver, with a dose-dependent effect.
Sources checked: PubMed/PMC (E-utilities esummary and abstracts on every PMID), written 2026-11-06.
Overview and evidence status
Source review: November 5, 2026. This introduction is separate from the practitioner excerpts below.
5-Amino-1MQ is a small molecule, not a peptide. The cited NNMT-inhibition study used mice with diet-induced obesity. It is preclinical evidence, not a demonstration of efficacy or safety in people. The chemical-identity record does not establish drug approval, and this source index makes no claim of FDA approval.
STOP Combining Retatrutide and Tirzepatide - Dr Trevor Bachmeyer (3×) · 2026-03-25read the hosted transcript
Ask the 5-Amino-1MQ Librarian
Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.
What have the teachers said about 5-Amino-1MQ? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.
AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.